Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$27,000.00
Neuroimaging of the Glymphatic Clearance System in Pathologically-Confirmed Alzheimer's
FY 2024-25
Summary
The glymphatic clearance system (GCS) is a recently discovered brain pathway responsible for clearing waste within the brain and thus is vital for maintaining brain health. In Alzheimer disease (AD), dysfunction of the GCS has been linked to declined cognitive functioning via the impaired clearance of cellular waste products. Current methods for studying GCS function in humans are costly and invasive (e.g., surgery, repeated magnetic resonance imaging (MRI)), rendering them unsuitable for assessing AD. Advanced MRI techniques offer non-invasive (NI) methods to evaluate GCS function. However, such evaluations provide limited understanding of GCS activity and its impairment. The determination of NI imaging markers of GCS function is important to studying the disease processes underlying the clinical presentation of AD. This study seeks to address this gap by comparing NI imaging markers with pathological data from post-mortem reports - the gold standard for AD diagnosis. Using data from 8,150+ patients in North America largest AD database, we will analyze pathologically confirmed AD patients with matched controls. The study will also integrate advanced MRI techniques with established clinical measures of AD to evaluate how well imaging markers of GCS reflect actual brain changes and associated behavioral outcomes in AD. This research will be the first to examine NI imaging methods for studying GCS dysfunction in AD by linking these markers directly to brain pathology and clinical data. By doing so, it will deepen our understanding of the physiological processes and related GCS dysfunction driving AD. Furthermore, the findings will provide clinicians with insights into the use of NI imaging markers to assess GCS function in AD while avoiding invasive alternatives.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
530239
Name
Fernandes Francis Ashley
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Neuroimaging of the Glymphatic Clearance System in Pathologically-Confirmed Alzheimer's
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Alzheimer’S Disease; Brain; Choroid Plexus; Cognition; Diffusion Tensor Imaging Along The Perivascular Space; Glymphatic Clearance System; Magnetic Resonance Imaging; Neuropathology; Perivascular Space; Sleep
Abstract
The glymphatic clearance system (GCS) is a recently discovered brain pathway responsible for clearing waste within the brain and thus is vital for maintaining brain health. In Alzheimer disease (AD), dysfunction of the GCS has been linked to declined cognitive functioning via the impaired clearance of cellular waste products. Current methods for studying GCS function in humans are costly and invasive (e.g., surgery, repeated magnetic resonance imaging (MRI)), rendering them unsuitable for assessing AD. Advanced MRI techniques offer non-invasive (NI) methods to evaluate GCS function. However, such evaluations provide limited understanding of GCS activity and its impairment. The determination of NI imaging markers of GCS function is important to studying the disease processes underlying the clinical presentation of AD. This study seeks to address this gap by comparing NI imaging markers with pathological data from post-mortem reports - the gold standard for AD diagnosis. Using data from 8,150+ patients in North America largest AD database, we will analyze pathologically confirmed AD patients with matched controls. The study will also integrate advanced MRI techniques with established clinical measures of AD to evaluate how well imaging markers of GCS reflect actual brain changes and associated behavioral outcomes in AD. This research will be the first to examine NI imaging methods for studying GCS dysfunction in AD by linking these markers directly to brain pathology and clinical data. By doing so, it will deepen our understanding of the physiological processes and related GCS dysfunction driving AD. Furthermore, the findings will provide clinicians with insights into the use of NI imaging markers to assess GCS function in AD while avoiding invasive alternatives.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Fernandes, Francis Ashley
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~